Home >Newsletters >March 2004>News
 
ASA NEWSLETTER
 
 
March 2004
Volume 68
Number 3

Anesthesiologists and Transfusion Medicine: New Drugs, Better Education

Gregory A. Nuttall, M.D., Chair
Committee on Transfusion Medicine


The Committee on Transfusion Medicine performed a survey of ASA members’ transfusion practices in 2002. The results of this survey were published in the December 2003 issue of Anesthesiology. Though anesthesiologists transfuse a large percentage of the blood used in the United States, we found that a majority of anesthesiologists rarely transfuse blood in the operating room. Certain subspecialty groups transfuse blood frequently due to the nature of the surgical procedures in which they are involved. We also found that most anesthesiologists generally follow the guidelines published by ASA for transfusion of blood products.1 The survey identified many areas where education could improve transfusion practices. The committee is focusing its educational efforts in these areas.

The committee continues its liaison activities with other organizations involved in blood transfusions. Blood shortages continue to occasionally limit the number of surgeries that can be performed at many hospitals.

Recently a number of drugs have become available for the treatment of excessive bleeding. There have been numerous case reports, case series and retrospective studies documenting success in controlling excessive bleeding in patients refractory to standard blood transfusion therapy with the use of the drug recombinant human factor VIIa. This drug has been approved by the Food and Drug Administration for the treatment of hemophilia and is used “off label” for the treatment of excessive bleeding in the operating room. The Committee on Transfusion Medicine will be providing a panel presentation at the 2004 ASA Annual Meeting on “Excessive Surgical Bleeding: Role of rVIIa and Other Procoagulant Drugs.” This panel will address the morbidity of excessive bleeding, the etiologies of coagulopathy, the risks of thrombosis and the mechanisms of action, pharmacology, safety and efficacy of rVIIa and other procoagulant drugs.


Reference:
1. Practice guidelines for blood component therapy: A report by the American Society of Anesthesiologists Task Force on Blood Component Therapy. Anesthesiology. 1996; 84:732-747.



    Gregory A. Nuttall, M.D., is Associate Professor of Anesthesiology, Mayo Clinic College of Medicine, Rochester, Minnesota.
Gregory A. Nuttall, M.D.

return to top


 

FEATURES

Quality Management and Departmental Administration


ARTICLES

DEPARTMENTS


The views expressed herein are those of the authors and do not necessarily represent or reflect the views, policies or actions of the American Society of Anesthesiologists.

2004 NL Subject Index

2004 NL Author Index

NL Archives


Information for Authors